Last Price$86.0(2.7%)
Market Cap$34.9B
LTM Free Cash Flow margin
11.3%
5Y avg
10.9%
Medical - Devices industry
median
(25.8%)
Stock quality & Intrinsic value
7/10
(0.5%) overvalued
DexCom, Inc. Free Cash Flow margin
Annual
Quarterly
LTM
Industry median
Company stand-alone
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow margin | 0.0% | (2,170.1%) | (792.1%) | (406.0%) | (142.7%) | (101.9%) | (50.0%) | (42.6%) | (3.4%) | 2.9% | 3.9% | 0.1% | 3.6% | 5.4% | 9.1% | 14.4% | 2.2% | 10.5% | 14.1% | 0.0% |
Overvalued or undervalued?
Check the intrinsic value for DXCM
and see if it's the right time to invest.
DexCom, Inc. (DXCM) Free Cash Flow margin comparison analysis
General
LTM Free Cash Flow margin
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
DexCom, Inc.DXCM
11.3%
11.3%
(1.4%)
14.3%
Median Peer Set
15.3%
4.1%
126.3%
11.8%
Zimmer Biomet Holdings, Inc.ZBH
20.0%
6.5%
253.2%
13.8%
Medtronic plcMDT
16.5%
3.6%
(2.1%)
11.4%
Insulet CorporationPODD
15.9%
30.0%
4,364.6%
12.2%
Align Technology, Inc.ALGN
15.6%
3.4%
26.0%
11.5%
Stryker CorporationSYK
15.4%
10.2%
(5.8%)
13.2%
Abbott LaboratoriesABT
15.1%
4.6%
134.5%
31.9%
Boston Scientific CorporationBSX
14.6%
17.6%
16.7%
11.1%
STERIS plcSTE
13.9%
3.6%
257.9%
7.4%
Edwards Lifesciences CorporationEW
8.6%
(9.4%)
202.2%
76.7%
Koninklijke Philips N.V.PHG
1.5%
(0.8%)
118.1%
(3.9%)
DXCM key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 0.0 0.0% | 2.2 0.0% | 4.6 113.2% | 9.8 112.6% | 29.7 201.8% | 48.6 63.8% | 76.3 56.8% | 99.9 31.0% | 160.0 60.2% | 259.2 62.0% | 402.0 55.1% | 573.3 42.6% | 718.5 25.3% | 1,031.6 43.6% | 1,476.0 43.1% | 1,926.7 30.5% | 2,448.5 27.1% | 2,909.8 18.8% | 3,622.3 24.5% | 4,033.0 11.3% |
| Cost of Goods Sold (COGS) | 0.0 | 11.0 | 12.7 | 15.4 | 26.0 | 30.2 | 40.4 | 53.3 | 59.9 | 82.9 | 123.6 | 194.9 | 226.4 | 367.7 | 544.5 | 646.6 | 768.0 | 1,026.7 | 1,333.4 | 1,567.3 |
% margin | 0.0 0.0% | (8.8) (405.1%) | (8.1) (175.3%) | (5.5) (56.2%) | 3.7 12.3% | 18.4 37.9% | 35.8 47.0% | 46.6 46.6% | 100.1 62.6% | 176.3 68.0% | 278.4 69.3% | 378.4 66.0% | 492.1 68.5% | 663.9 64.4% | 931.5 63.1% | 1,280.1 66.4% | 1,680.5 68.6% | 1,883.1 64.7% | 2,288.9 63.2% | 2,465.7 61.1% |
| Operating Expenses | 32.4 | 40.5 | 38.6 | 47.3 | 49.5 | 63.7 | 80.7 | 102.3 | 129.0 | 197.8 | 335.5 | 442.3 | 534.6 | 850.2 | 789.2 | 980.6 | 1,414.7 | 1,491.9 | 1,691.2 | 1,865.7 |
| Research & Development Expenses (R&D) | 26.8 | 19.4 | 16.1 | 19.6 | 14.3 | 23.2 | 30.7 | 39.5 | 44.8 | 69.4 | 137.5 | 156.1 | 185.4 | 417.4 | 273.5 | 359.9 | 604.2 | 484.2 | 505.8 | 552.4 |
| Selling, General & Administrative Expenses (SG&A) | 5.7 | 21.1 | 22.4 | 27.7 | 35.2 | 40.5 | 49.9 | 62.8 | 84.2 | 128.4 | 198.0 | 286.2 | 349.2 | 432.8 | 515.7 | 620.7 | 810.5 | 1,000.2 | 1,185.4 | 1,285.8 |
% margin | (32.4) 0.0% | (49.3) (2,273.0%) | (46.7) (1,008.8%) | (52.8) (537.0%) | (45.8) (154.4%) | (45.3) (93.1%) | (44.8) (58.8%) | (55.7) (55.8%) | (28.9) (18.1%) | (21.5) (8.3%) | (57.1) (14.2%) | (63.9) (11.1%) | (42.5) (5.9%) | (186.3) (18.1%) | 142.3 9.6% | 299.5 15.5% | 175.4 7.2% | 391.2 13.4% | 597.7 16.5% | 600.0 14.9% |
| Interest Income | 0.0 | 0.0 | 0.0 | 1.2 | 0.4 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.4 | 3.3 | 2.4 | 26.4 | 16.1 | 1.7 | 18.0 | 135.0 | 0.0 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 7.3 | 8.0 | 1.5 | 0.0 | 0.2 | 0.9 | 0.8 | 0.4 | 0.7 | 12.8 | 22.7 | 60.3 | 84.7 | 102.0 | 18.6 | 20.3 | 0.0 |
| Pre-tax Income | (30,889.7) | (46.6) | (45.9) | (55.2) | (53.5) | (55.2) | (44.7) | (55.8) | (29.8) | (22.3) | (57.5) | (64.9) | (48.6) | (126.5) | 104.2 | 225.0 | 173.9 | 390.8 | 710.4 | 709.0 |
% effective tax rate | (30,858.9) 99.9% | 0.0 (0.0%) | 0.0 0.0% | 2.4 (4.3%) | 0.0 0.0% | 9.9 (17.9%) | (0.1) 0.2% | (1.3) 2.3% | 0.0 0.0% | 0.1 (0.4%) | 0.1 (0.2%) | 0.7 (1.1%) | 1.6 (3.3%) | 0.6 (0.5%) | 3.1 3.0% | (268.6) (119.4%) | 19.2 11.0% | 49.6 12.7% | 168.9 23.8% | 132.8 18.7% |
% margin | (30.8) 0.0% | (46.6) (2,147.6%) | (45.9) (991.5%) | (55.2) (560.9%) | (53.5) (180.3%) | (55.2) (113.4%) | (44.7) (58.7%) | (54.5) (54.6%) | (29.8) (18.6%) | (22.4) (8.6%) | (57.6) (14.3%) | (65.6) (11.4%) | (50.2) (7.0%) | (127.1) (12.3%) | 101.1 6.8% | 493.6 25.6% | 154.7 6.3% | 341.2 11.7% | 541.5 14.9% | 576.2 14.3% |
| EPS | (0.41) | (0.43) | (0.41) | (0.47) | (0.30) | (0.24) | (0.17) | (0.20) | (0.10) | (0.07) | (0.18) | (0.20) | (0.15) | (0.36) | 0.28 | 1.31 | 0.40 | 0.88 | 1.44 | 1.42 |
| Diluted EPS | (0.41) | (0.43) | (0.41) | (0.47) | (0.30) | (0.24) | (0.17) | (0.20) | (0.10) | (0.07) | (0.18) | (0.20) | (0.15) | (0.36) | 0.27 | 1.27 | 0.36 | 0.80 | 1.30 | 1.40 |
% margin | (29.7) 0.0% | (46.6) (2,148.7%) | (43.3) (936.8%) | (49.8) (506.1%) | (43.1) (145.2%) | (51.2) (105.3%) | (41.0) (53.7%) | (49.0) (49.0%) | (21.9) (13.7%) | (13.1) (5.1%) | (46.3) (11.5%) | (49.2) (8.6%) | (19.7) (2.7%) | (74.7) (7.2%) | 213.2 14.4% | 376.8 19.6% | 377.5 15.4% | 565.3 19.4% | 916.7 25.3% | 840.7 20.8% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is DexCom, Inc.'s Free Cash Flow margin?
As of today, Microsoft Corp's last 12-month Free Cash Flow margin is 11.3%, based on the financial report for Dec 31, 2024 (Q4’2024). The average annual Free Cash Flow margin for DexCom, Inc. have been 10.6% over the past three years, and 11.4% over the past five years.
2) Is DexCom, Inc.'s Free Cash Flow margin Good?
As of today, DexCom, Inc.'s Free Cash Flow margin is 11.3%, which is higher than industry median of (25.8%). It indicates that DexCom, Inc.'s Free Cash Flow margin is Good.